Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals

This article was originally published in The Tan Sheet

Executive Summary

FDA seeks research proposals to evaluate consumers’ understanding of OTC drugs bearing umbrella brand names. The agency says the data also will benefit regulatory action and future guidance development as well as provide knowledge to scientists studying risk communication of drugs.

Advertisement

Related Content

OTC Umbrella Branding Soaked By Regulatory Storm In Draft Guidance – CHPA
Draft Guidance On Developing Drug Names Calls For Simulation Studies

Topics

Advertisement
UsernamePublicRestriction

Register